A Study In Neuromyelitis Optica Spectrum Disorder (NMOSD) With Satralizumab As An Intervention
Status:
Not yet recruiting
Trial end date:
2025-07-05
Target enrollment:
Participant gender:
Summary
Objective of the trial is to describe the efficacy and safety of satralizumab in patients
with aquaporin-4 (AQP4) antibody seropositive NMOSD, either treatment naive or inadequate
responders to previous treatment with rituximab (RTX) (or its biosimilar)